Meeting
2023 ASCO Annual Meeting
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
Authors
Stephanie Gaillard
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Stephanie Gaillard , Mary Wilkinson , Lainie P. Martin , Amy Deery , Amanda Langsdale , Asnakech Bayable , Marianna Zahurak , Peng Huang , Deborah Kay Armstrong , Ie-Ming Shih , Tian-Li Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03246074
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5574)
DOI
10.1200/JCO.2023.41.16_suppl.5574
Abstract #
5574
Poster Bd #
269
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
First Author: Nehal J. Lakhani
Poster
2017 ASCO Annual Meeting
A phase I trial of mifepristone (M), carboplatin (C), and gemcitabine (G) in advanced breast and ovarian cancer.
First Author: Erica Michelle Stringer
Poster
2016 ASCO Annual Meeting
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
First Author: Yong Sang Hong
Poster
2015 ASCO Annual Meeting
The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer.
First Author: Michael Hans Robert Eichbaum